Skip to content
StockMarketAgent
Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

AGEN stock hub

Agenus Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

AGENis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
146.7M
NASDAQ
Market data

Live price

Current market quote for this ticker.

Current price
AGEN
In the news

Latest news · AGEN

Recent company headlines from major financial publishers.

Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window
EPS estimate
Revenue estimate
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E1.8
P25 12.3P50 18.4P75 33.1
Trailing P/En/a
P25 14.9P50 23.2P75 38.5
ROEn/a
P25 -105.6P50 -46.5P75 -3.1
ROICn/a
P25 -63.1P50 -27.3P75 0.5
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All AGEN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
211
Groups with data
11
Currency
USD
Showing 211 of 211 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

25
MetricValue
Cik
0001098972
Company name
Agenus Inc.
Country
United States
Country code
US
Cusip
00847G804
Employees
81
Employees Change
-235%
Employees Change Percent
-74.37
Enterprise value
$199.6M
Exchange
NASDAQ
Financial currency
USD
First seen
2026-05-09
Industry
Biotechnology
IPO Date
2000-02-04
Isin
US00847G8042
Last refreshed
2026-05-10
Market cap
$146.7M
Market cap category
Micro-Cap
Price
$3.82
Price currency
USD
Rev Per Employee
1,409,827.16x
Sector
Healthcare
Sic
2836
Symbol
AGEN
Website
https://www.agenusbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

7
MetricValue
Earnings Yield
-0.07%
EV Sales Forward
0.87x
EV/Sales
1.75x
FCF yield
-52.63%
Forward P/E
1.82x
P/S ratio
1.28x
PS Forward
0.64x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

15
MetricValue
EBIT Margin
-18%
EBITDA Margin
-9.24%
Gross margin
96.52%
Gross Profit
$110.2M
Gross Profit Growth
21.15%
Gross Profit Growth Q
-24.47%
Net Income
$-101,000
Net Income Growth Quarters
5%
Net Income Growth Years
2%
Pretax Margin
-2.7%
Profit Margin
0.1%
Profit Per Employee
$-1,247
ROA
-5.67
Roa5y
-16.15
ROCE
21.26

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

14
MetricValue
Cagr10y
-23.96%
Cagr15y
-19.93%
Cagr1y
29.52%
Cagr20y
-18.62%
Cagr3y
-50.44%
Cagr5y
-42.4%
EPS Growth Quarters
10
EPS Growth Years
0
Revenue Growth
10.37x
Revenue Growth Q
27.45x
Revenue Growth Quarters
3x
Revenue Growth Years
1x
Revenue Growth3 Y
5.22x
Revenue Growth5 Y
5.31x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

16
MetricValue
Asset Turnover
$0.5
Assets
$226.8M
Cash
$3M
Current Assets
$133.4M
Current Liabilities
$323.5M
Debt
$55.9M
Equity
$-277.9M
Interest Coverage
-0.37
Liabilities
$504.7M
Long Term Assets
$93.4M
Long Term Liabilities
$181.2M
Net Cash
$-52.9M
Net Cash By Market Cap
$-36.08
Tangible Book Value
$-298.2M
Tangible Book Value Per Share
$-8.44
WACC
31.15

Liquidity

Current-asset coverage and working-capital efficiency metrics.

5
MetricValue
Current ratio
0.41
Net Working Capital
$-147.3M
Quick ratio
0.03
Working Capital
$-190.1M
Working Capital Turnover
$-0.62

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

2
MetricValue
Buyback Yield
-38.47%
Dividend Yield
0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

42
MetricValue
10Y total return
-93.53%
1Y total return
29.49%
200-day SMA
3.96
3Y total return
-87.83%
50-day SMA
3.74
50-day SMA vs 200-day SMA
50under200
5Y total return
-93.66%
All Time High
8,580
All Time High Change
-99.96%
All Time High Date
2000-02-07
All Time Low
1.38
All Time Low Change
176.81%
All Time Low Date
2025-04-07
ATR
0.31
Beta
1.6
Beta1y
2.43
Beta2y
2.44
Ch YTD
21.66
High
3.93
High52
7.34
High52 Date
2025-07-11
High52ch
-47.96%
Low
3.71
Low52
2.71
Low52 Date
2026-02-05
Low52ch
40.96%
Ma50ch
2.11%
Premarket Change Percent
0.53
Premarket Price
$3.77
Premarket Volume
1,683
Price vs 200-day SMA
-3.54%
RSI
47.68
RSI Monthly
37.46
RSI Weekly
51.16
Sharpe ratio
0.7x
Sortino ratio
1.2
Total Return
-38.47%
Tr YTD
21.66
Tr15y
-96.44%
Tr1m
-5.91%
Tr1w
-0.52%
Tr3m
29.93%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

9
MetricValue
Analyst Count
2
Analyst Ratings
Buy
Earnings EPS Estimate
$1.83
Earnings Revenue Estimate
129,500,000x
Earnings Revenue Estimate Growth
438.1x
Operating Income
$-20.6M
Operating margin
-18
Price target
$14.5
Price Target Change
$280

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

11
MetricValue
Float
35,619,321%
Float Percent
92.76%
Net Borrowing
2,349,000
Shares Insiders
1.67%
Shares Institutions
26.87%
Shares Out
38,398,354
Shares Qo Q
4.64%
Shares Yo Y
38.47%
Short Float
12.2%
Short Ratio
4.53
Short Shares
11.32

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

65
MetricValue
Adjusted FCF
$-91M
Average Volume
1,051,957.3x
Bv Per Share
-7.68
CAPEX
$-6,000
Ch10y
-93.65
Ch15y
-96.5
Ch1m
-5.91
Ch1w
-0.52
Ch1y
29.49
Ch20y
-98.41
Ch3m
29.93
Ch3y
-87.83
Ch5y
-93.78
Ch6m
-4.02
Change
1.87%
Change From Open
1.33
Close
3.75
Days Gap
0.53
Depreciation Amortization
9,999,000
Dollar Volume
2,374,928.4
Earnings Date
2026-05-11
Earnings Time
bmo
EBIT
$-20.6M
EBITDA
$-10.6M
EPS
$-0
F Score
3
FCF
$-77.2M
FCF EV Yield
-38.68x
FCF Per Share
$-2.01
Financing CF
36,593,000
Fiscal Year End
December
Founded
1,994
Goodwill
24,092,000
Investing CF
1,194,000
Is Primary Listing
1
Is Spac
No
Last Earnings Date
2026-03-16
Last Report Date
2025-12-31
Last Split Date
2024-04-12
Last Split Type
Reverse
Last10k Filing Date
2026-03-16
Ma150
3.73
Ma150ch
2.52%
Ma20
4.11
Ma20ch
-7.15%
Net CF
-39,361,000
Next Earnings Date
2026-05-11
Open
3.77
Optionable
Yes
Position In Range
51.16
Post Close
3.82
Postmarket Change Percent
2.09
Postmarket Price
$3.9
Ppne
23,214,000
Pre Close
3.75
Price Date
2026-05-08
Relative Volume
0.59x
Revenue
114,196,000x
SBC By Revenue
12.06x
Share Based Comp
13,770,000
Tr20y
-98.38%
Tr6m
-4.02%
Us State
Massachusetts
Volume
621,709
Z Score
-14.14
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does AGEN pay a dividend?

Capital-return profile for this ticker.

Performance

AGEN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
+29.5%
S&P 500 1Y: n/a
3Y total return
-87.8%
S&P 500 3Y: n/a
5Y total return
-93.7%
S&P 500 5Y: n/a
10Y total return
-93.5%
S&P 500 10Y: n/a
Ownership

Who owns AGEN?

Insider, institutional, and short-interest positioning.

Institutional ownership
+26.9%
Float: +92.8% of shares outstanding
Insider ownership
+1.7%
Stake held by company insiders. Higher generally signals alignment.
Short interest
+12.2%
4.5 days to cover
Y/Y dilution
+38.5%
Negative means the company is buying back shares.
Technical

AGEN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
47.7
Neutral momentum band
Price vs 200-day MA
-3.5%
50/200-day relationship not available
Beta (5Y)
1.60
More volatile than the market
Sharpe ratio
0.70
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About AGEN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AGEN stock rating?

Agenus Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AGEN analysis?

The full report lives at /stocks/AGEN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AGEN?

The latest report frames AGEN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AGEN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.